EMORY UNIVERSITY - Coronavirus Contracts

Contracts Vendors Agencies Categories States

Coronavirus Contracts

Tracking Federal Purchases to Fight the Coronavirus

Home › All Vendors › Vendor ›

EMORY UNIVERSITY

Total Committed Value of Federal Contracts

$6.47M

Total Contracts

Total Actions

Location

Atlanta, GA

Recent Contract Actions

Contracts can have multiple “contract actions”: This is how agencies spend money for a specific purpose, adjust the amount committed or change the contract in a way that doesn’t affect the amount. That last scenario is usually indicated by a $0 action. If there is a contract action for a negative amount, it generally means the contract was adjusted or canceled.

Description	Category	Agency	Signed	Amount Committed
SARS - COV-2 APPLIED RESEARCH FOR NCEZID	Physical Science Applied Research/Exploratory Development R&D	Centers for Disease Control and Prevention	November 23, 2020	$622,109
COVID-19: SERVICES TO MEASURE SARS-COV-2 VIRUS TITERS AND PERFORM NEUTRALIZATION ASSAYS	Laboratory Testing	National Institutes of Health	September 22, 2020	$78,561
SARS COV-2 BAA	Biomedical R&D	Centers for Disease Control and Prevention	September 17, 2020	$468,435
NIH TCF TASK AREA B-1 COVID-19; SPLIT CANS; $733,849.00 POP 09/01/2020-03/20/2022	Biomedical R&D	National Institutes of Health	September 08, 2020	$0
NIH TCF TASK B-1	Biomedical R&D	National Institutes of Health	August 21, 2020	$733,849
FY 2020 COVID-19 BAA TOPIC 2 - EMORY	Physical Science Applied Research/Exploratory Development R&D	Centers for Disease Control and Prevention	August 17, 2020	$348,253
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)	Biomedical Applied Research/Exploratory Development R&D	National Institutes of Health	August 01, 2020	$267,698
BLOOD DRAW #2 COVID 19	Drugs and Biologicals	Centers for Disease Control and Prevention	July 17, 2020	$144,666
TO DEVELOP EIDD-2801, THE 5'-ISOPROPHL ESTER PRODRUG OF THE BROADLY ACTIVE ANTIVIRAL RIBONUCLEOSIDE ANALOGUE EIDD-1931, FOR THE TREATMENT OF INFLUENZA INFECTIONS.	Biomedical Applied Research/Exploratory Development R&D	National Institutes of Health	June 11, 2020	-$5,227,387
COVID-19; NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)	Biomedical Applied Research/Exploratory Development R&D	National Institutes of Health	June 02, 2020	$2,176,035
SEROLOGICAL TESTING	Laboratory Testing	Centers for Disease Control and Prevention	May 14, 2020	$5,082
TO DEVELOP EIDD-2801, THE 5'-ISOPROPHL ESTER PRODRUG OF THE BROADLY ACTIVE ANTIVIRAL RIBONUCLEOSIDE ANALOGUE EIDD-1931, FOR THE TREATMENT OF INFLUENZA INFECTIONS.	Biomedical Applied Research/Exploratory Development R&D	National Institutes of Health	May 05, 2020	$0
SEROLOGICAL TESTING	Laboratory Testing	Centers for Disease Control and Prevention	April 30, 2020	$57,372
COVID 19 TESTING	Laboratory Testing	Department of Veterans Affairs	April 29, 2020	$37,500
NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)	Biomedical Applied Research/Exploratory Development R&D	National Institutes of Health	April 28, 2020	$1,032,857
SEROLOGICAL TESTING	Laboratory Testing	Centers for Disease Control and Prevention	April 20, 2020	$492,604
TO DEVELOP EIDD-2801, THE 5'-ISOPROPHL ESTER PRODRUG OF THE BROADLY ACTIVE ANTIVIRAL RIBONUCLEOSIDE ANALOGUE EIDD-1931, FOR THE TREATMENT OF INFLUENZA INFECTIONS.	Biomedical Applied Research/Exploratory Development R&D	National Institutes of Health	April 10, 2020	$5,227,387

See this vendor on usaspending.gov ›

About this data

This data comes from the Federal Procurement Data System, which includes all contracts worth $10,000 or more. We look at all contracts that are tagged with the procurement code for COVID-19 or otherwise started in 2020 and contain “COVID-19” in the description. Department of Defense contracting data is subject to a 90-day delay before it appears in the data.